Elias Kröger

Associate
  • Stockholm
  • Languages:
    Swedish, English

Mandates

Mandate March 25, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Mark…

Mandate March 23, 2026

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a missi…

Mandate June 30, 2025

Vinge has advised Terranor Group AB in connection with its listing on Nasdaq First North Growth Market

Vinge has advised Terranor Group AB (publ) (“Terranor”) connection with its listing on Nasdaq First…

Mandate April 25, 2025

Vinge has advised Studentbostäder i Norden AB in connection with its rights issue

Vinge has advised Studentbostäder i Norden AB (publ), a real estate company whose shares are listed…

Mandate December 06, 2024

Vinge has advised Apotea in connection with its listing on Nasdaq Stockholm

Vinge has advised Apotea AB (publ) (“Apotea”) in connection with its listing on Nasdaq Stockholm. Th…

Mandate December 03, 2024

Vinge is advising Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of shares whereby Xspray…

Mandate June 04, 2024

Vinge has assisted Priveq in connection with the formation of Priveq Investment VII

Priveq, a leading Nordic lower mid-market growth and buyout investor, has closed its seventh fund, P…

Mandate April 03, 2024

Vinge has advised Tobii AB (publ) in connection with its rights issue

Vinge has advised Tobii AB (publ) in connection with a fully guaranteed rights issue of ordinary sha…

Mandate December 06, 2023

Vinge has advised Cell Impact in connection with its rights issue

Vinge has advised Cell Impact AB (publ) in connection with a partly guaranteed rights issue which wi…